Uses of Exsanron

Exsanron contains iron fumarate 162mg, folic acid 0.75mg, Vitamin B12 7.5mcg. Exsanron treats anemia caused by iron deficiency, folic acid deficiency in pregnant women, patients with intestinal bleeding, patients undergoing hemodialysis treatment, after surgery,...

Exsanron belongs to the group of vitamins and minerals that contain ingredients including:
Iron fumarate 162mg is an organic form of iron, which is essential for making hemoglobin - a part of blood cells. Iron fumarate is used to treat and prevent iron-deficiency anemia. Folic acid 0.75mg, also known as vitamin B9, is an indispensable factor in helping the body produce red blood cells and participate in the growth and division of cells as well as the formation of blood cells. . Folic acid plays a role in preventing neural tube defects when taken before or during the first week of pregnancy. In some studies, folic acid can also prevent heart defects and birth defects of the mouth such as cleft lip and palate in children. Vitamin B12 7.5 mcg, is a vitamin that plays an important role in helping your body produce red blood cells. Low levels of vitamin B12 disrupt the process of red blood cell formation. Healthy red blood cells are small and round in shape, but when vitamin B12 is deficient, red blood cells become large and oval in shape. Because of their large shape, red blood cells cannot move from the bone marrow into the bloodstream at a rapid rate. suitable level, causing megaloblastic anemia.

Exsanron is indicated for use in the treatment of diseases such as:
Iron deficiency anemia. Anemia due to folic acid deficiency. Gastrointestinal bleeding. The patient is on hemodialysis treatment. Patients after gastric bypass surgery. Used for the prevention of iron deficiency anemia and folic acid deficiency in pregnant and lactating women when dietary intake is insufficient. Patients with iron malabsorption such as: Partial or total gastrectomy, atrophic gastritis, chronic enteritis. Women menorrhagia, bleeding.

Treatment of iron deficiency anemia:
Teenagers (> 12 years old), adults: Take 1 tablet x 2 times/day. Use for 3 months. Pregnant women: take 1 tablet x 2 times/day. Use for 3 months. After 3 months, pregnant women should continue to follow an iron supplement regimen to prevent iron deficiency anemia. In case of supplementing with iron, folic acid and vitamin B12 due to insufficient dietary intake:
Teenagers (> 12 years old), adults: 1 tablet x 1 time/day orally for 3 months continuously. Pregnant women: 1 tablet x 1 time / day, take continuously for 6 months of pregnancy and continue for 3 - 6 months after giving birth.

Exsanron is available as a film-coated tablet for oral administration. Patients should carefully read the instructions for use of the drug on the leaflet. Take the medicine with a full glass of water. The drug should be taken away from meals (2 hours before or 1 hour after meals).
If the patient forgets a dose, take the missed dose as soon as he remembers, then use the medicine as usual. In case this dose is too close to the next dose, skip the missed dose and take the next scheduled dose. Do not take a double dose at a time.

Exsanron is contraindicated in the following cases:
Patients with hypersensitivity or allergy to Iron, Folic Acid, Vitamin B12 or any of the excipients of the drug. The patient has hemoglobinopathy. Patients with peptic ulcer, ulcerative colitis. Concomitant use with another iron-containing drug that is administered by a different route (injection). The patient required multiple blood transfusions.

Patients using Exsanron may experience some unwanted effects such as nausea, vomiting, constipation or diarrhea and other digestive disorders, black teeth. These undesirable effects can be minimized by taking the drug during or after a meal.

Exsanron is used to treat iron deficiency anemia or to supplement with iron, folic acid, and vitamin B12. The dosage of folic acid and vitamin B12 in Exsanron is not sufficient for the treatment of megaloblastic anemia. If used inappropriately, the hematologic manifestations can be reduced, while neurological syndromes remain undetected. Exsanron should be used with caution in patients with erythropoietic protoporphyria (EPP) syndrome. Exsanron contains iron, which can turn stools black. Iron overdose in children can be fatal, so keep Exsanron out of the reach of children. Effects on ability to drive and use machines: The drug does not affect the ability to drive and use machines. Use in pregnancy: Exsanron can be used in pregnant women. Supplementation of iron, folic acid and vitamin B12 for pregnant women is necessary to prevent maternal anemia, sepsis, low birth weight and premature birth. Folic acid supplementation should be started as early as possible (ideally before conception and during the first trimester) to prevent neural tube defects. Exsanron should be supplemented for pregnant women because of the above benefits. Vitamin B12 plays an important role in the development of the nervous system, brain and for the general physical development of the fetus. Therefore, vitamin B12 supplementation for pregnant women is necessary. Use of drugs in lactation: Iron, folic acid and vitamin B12 are all secreted into breast milk. Breastfeeding women can use Exsanron.

When using Exsanron, patients may experience drug interactions as follows:
Exsanron forms a complex when taken simultaneously with tetracycline, leading to decreased absorption of both drugs. Therefore, it should be taken 2-3 hours apart. Exsanron also forms complexes with acetohydroxamic acid. Absorption of Exsanron may be reduced in the presence of antacids and proton pump inhibitors that reduce gastric acid. Absorption of Exsanron is reduced by food (eg, tea, coffee, eggs, milk, cereals), neomycin and cholestyramine. Bicarbonate, carbonate, oxalate or phosphate drugs can affect the absorption of Exsanron by forming non-absorbable complexes. Absorption of Exsanron is increased by oral administration of citric acid or vitamin C. Absorption of Exsanron is decreased by oral calcium, magnesium salts and other mineral supplements, zinc and trientin. If both Exsanron and trientin must be used, they should be taken apart from each other. Response to Exsanron may be delayed in patients receiving systemic chloramphenicol. Chloramphenicol slows the release of Exsanron and the binding of Exsanron to red blood cells by interfering with erythropoiesis. The antihypertensive effect of methyldopa is reduced by Exsanron. Concomitant use of Exsanron and dimercaprol should be avoided because toxic complexes may be formed. Exsanron reduces the absorption of fluoroquinolones, levodopa, carbidopa, entacapone, bisphosphonates, penicillamine, thyroid hormones such as levothyroxine (taken at least 2 hours apart), mycophenolate, cefdinir and zinc. Exsanron reduces the absorption of eltrombopag (taken at least 4 hours apart). Serum concentrations of anticonvulsants such as phenobarbital, phenytoin and primidone may be decreased when co-administered with folate-containing drugs such as Exsanron Concomitant use of Exsanron with raltitrexed should be avoided. Absorption of Exsanron may be reduced by sulfasalazine. Absorption of Exsanron from the gastrointestinal tract may be reduced when co-administered with neomycin, aminosalicylic acid, histamine H2-receptor antagonists and colchicine. Serum concentrations may be decreased when used concomitantly with oral contraceptives. Oral administration of chloramphenicol may reduce the effect of Exsanron in anemia. Omeprazole reduces gastric acid, thus reducing the absorption of Exsanron.